CytoGenix and USAMRIID Forge Biodefense Vaccines Partnership

CytoGenix entered into a CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop and test synDNA™ vaccines for the prevention of disease caused by the Ebola virus and several strains of equine encephalitis viruses.

“These disease targets are listed as Category A & B bioterrorism agents/diseases by the Centers for Disease Control,” points out Malcolm Skolnick, CEO.

“Data collected under this CRADA will help to demonstrate the validity of use of synDNA™ vaccines in rapid response platforms, including the protection of our nation’s military personnel, health providers and other first responders, as well as the general population against a spectrum of existing and emerging terroristic and other infectious diseases.”